The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation.
We asked whether the antiangiogenic action of 16K human PRL (hPRL), in addition to blocking mitogen-induced vascular endothelial cell proliferation, involved activation of programmed cell death. Treatment with recombinant 16K hPRL increased DNA fragmentation in cultured bovine brain capillary endothelial (BBE) and human umbilical vein endothelial (HUVE) cells in a time- and dose-dependent fashion, independent of the serum concentration. The activation of apoptosis by 16K hPRL was specific for endothelial cells, and the activity of the peptide could be inhibited by heat denaturation, trypsin digestion, and immunoneutralization, but not by treatment with the endotoxin blocker, polymyxin-B. 16K hPRL-induced apoptosis was correlated with the rapid activation of caspases 1 and 3 and was blocked by pharmacological inhibition of caspase activity. Caspase activation was followed by inactivation of two caspase substrates, poly(ADP-ribose) polymerase (PARP) and the inhibitor of caspase-activated deoxyribonuclease (DNase) (ICAD). Furthermore, 16K hPRL increased the conversion of Bcl-X to its proapoptotic form, suggesting that the Bcl-2 protein family may also be involved in 16K hPRL-induced apoptosis. These findings support the hypothesis that the antiangiogenic action of 16K hPRL includes the activation of programmed cell death of vascular endothelial cells.
Martini
J F
JF
Center for Reproductive Sciences, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California School of Medicine, San Francisco 94143, USA.
Piot
C
C
Humeau
L M
LM
Struman
I
I
Martial
J A
JA
Weiner
R I
RI
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D020169:Caspases / Q000378:metabolism*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D004247:DNA / Q000378:metabolism; D053938:DNA Fragmentation / Q000187:drug effects; D004340:Drug Contamination; D004730:Endothelium, Vascular / Q000166:cytology*; D004731:Endotoxins / Q000494:pharmacology; D004789:Enzyme Activation / Q000187:drug effects; D004926:Escherichia coli; D005260:Female; D006358:Hot Temperature; D006801:Humans; D008970:Molecular Weight; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D010446:Peptide Fragments / Q000276:immunology / Q000494:pharmacology*; D011388:Prolactin / Q000276:immunology / Q000494:pharmacology*; D011489:Protein Denaturation; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D011981:Receptors, Prolactin / Q000502:physiology; D011986:Receptors, Somatotropin / Q000502:physiology; D011994:Recombinant Proteins / Q000494:pharmacology; D014357:Trypsin / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D004731:Endotoxins; D010446:Peptide Fragments; D019253:Proto-Oncogene Proteins c-bcl-2; D011981:Receptors, Prolactin; D011986:Receptors, Somatotropin; D011994:Recombinant Proteins; D011388:Prolactin; D004247:DNA; D014357:Trypsin; D020169:Caspases